<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521896</url>
  </required_header>
  <id_info>
    <org_study_id>CP1-001</org_study_id>
    <nct_id>NCT02521896</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study to Evaluate Access to Pulmonary Veins for Treatment of Paroxysmal AF</brief_title>
  <official_title>Vado™ Steerable Sheath System; A Safety and Performance Study to Evaluate Access to the Pulmonary Veins in the Treatment of Paroxysmal and Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kalila Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kalila Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to assess the safety and performance of the Vado™ Steerable Sheath in&#xD;
      facilitating ease of access to the pulmonary veins (PV) for the treatment of paroxysmal&#xD;
      atrial fibrillation and persistent atrial fibrillation (AF). The study will be a prospective,&#xD;
      single-center, non-randomized investigation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design for this study involves the sequential enrollment of patients with documented&#xD;
      paroxysmal atrial fibrillation who have had two (2) or more AF episodes for at least 30&#xD;
      seconds in length within six (6) months prior to enrollment. Target population shall be&#xD;
      selected from the treatable AF population that meets both inclusion/exclusion criteria.It is&#xD;
      intended that the Vado Steerable Sheath will be used as part of standard clinical workflow&#xD;
      procedures, with no procedural deviations relative to other procedures requiring steerable&#xD;
      sheaths. Individual subjects will be studied during mapping and ablation procedures and&#xD;
      followed until release from hospital post procedure per institutional standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of adverse device related events at release from hospital post procedure per institutional standard of care</measure>
    <time_frame>Procedure through 7 day clinical follow up</time_frame>
    <description>Steerability and positioning to facilitate catheter placement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemostasis and Visibility of the steerable sheath</measure>
    <time_frame>Procedure through 7 day clinical follow up</time_frame>
    <description>Safe event free insertion of the steerable sheath system in the femoral vein</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Steerable sheath for intracardiac access</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Steerable Sheath System</intervention_name>
    <description>The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.</description>
    <arm_group_label>Steerable sheath for intracardiac access</arm_group_label>
    <other_name>Vado Steerable Sheath</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  suitable candidate for intra-cardiac mapping for arrhythmias with documented PAF&#xD;
             defined by HRS Criteria.&#xD;
&#xD;
          -  Eighteen to Eighty years of age&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intracardiac thrombus, tumor or other abnormality that precludes catheter introduction&#xD;
             and placement&#xD;
&#xD;
          -  Severe cerebrovascular disease or history of cerebrovascular event within one (1)&#xD;
             month&#xD;
&#xD;
          -  Patients with severely impaired kidney function as measured by a Cockcroft-Gault&#xD;
             Glomerular Filtration Rate (GFR) 3 with a GFR &lt; 29.&#xD;
&#xD;
          -  Active gastrointestinal bleeding, infection or fever (&gt; 100.5/38C)&#xD;
&#xD;
          -  Severe co morbidity or Short life expectancy (&lt;1 year) due to other illnesses such as&#xD;
             cancer, pulmonary, hepatic or renal disease&#xD;
&#xD;
          -  Structural heart disease of clinical significance including&#xD;
&#xD;
               -  Symptoms of congestive heart failure including, but not limited to, NYHA Class&#xD;
                  III or IV CHF and/or documented ejection fraction &lt; 40% measured by acceptable&#xD;
                  cardiac testing&#xD;
&#xD;
               -  Stable/unstable angina or ongoing myocardial ischemia&#xD;
&#xD;
               -  Myocardial infarction (MI) within three months of enrollment&#xD;
&#xD;
               -  Aortic or mitral valve disease &gt; Grade II&#xD;
&#xD;
               -  Congenital heart disease (not including ASD or PFO without a right to left shunt)&#xD;
                  where the underlying abnormality increases the risk of an ablative procedure&#xD;
&#xD;
          -  Enrollment in any other ongoing arrhythmia study protocol&#xD;
&#xD;
          -  Any ventricular tachyarrhythmia currently being treated where the arrhythmia or the&#xD;
             management may interfere with this study&#xD;
&#xD;
          -  Active infection or sepsis&#xD;
&#xD;
          -  Female patient is pregnant or lactating&#xD;
&#xD;
          -  Untreatable allergy to contrast media&#xD;
&#xD;
          -  Any diagnosis of atrial fibrillation secondary to electrolyte imbalance, thyroid&#xD;
             disease, or any other reversible or non-cardiovascular causes&#xD;
&#xD;
          -  History of blood clotting (bleeding or thrombotic) abnormalities&#xD;
&#xD;
          -  Known sensitivities to heparin or warfarin&#xD;
&#xD;
          -  Severe COPD (identified by an FEV1 &lt;1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Crozier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christchurch Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Daly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christchurch Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Piorkowski C, Eitel C, Rolf S, Bode K, Sommer P, Gaspar T, Kircher S, Wetzel U, Parwani AS, Boldt LH, Mende M, Bollmann A, Husser D, Dagres N, Esato M, Arya A, Haverkamp W, Hindricks G. Steerable versus nonsteerable sheath technology in atrial fibrillation ablation: a prospective, randomized study. Circ Arrhythm Electrophysiol. 2011 Apr;4(2):157-65. doi: 10.1161/CIRCEP.110.957761. Epub 2011 Jan 19.</citation>
    <PMID>21248246</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

